
Dawn Lauryn Hershman MD
Hematologic Oncology
Professor of Medicine, Columbia/NYP
161 Fort Washington AveNew York, NY 10032
Overview of Dr. Hershman
Dr. Dawn Hershman is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Albert Einstein College of Medicine and has been in practice 32 years. Dr. Hershman accepts several types of health insurance, listed below. She is one of 82 doctors at New York-Presbyterian Hospital and one of 25 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Hematology. She has more than 100 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1998 - 2001
Columbia University School of Public HealthMSc, Biostatistics, 2001
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1998
Albert Einstein College of MedicineClass of 1994
University of California, Los AngelesB.A., Psychology, 1987
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 2022 - 2027
NY State Medical License 1995 - 2027
CT State Medical License 2024 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2017
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2013-2017
- CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2013-2017
Clinical Trials
- Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
- S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
- Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial Start of enrollment: 2006 Apr 24
Publications & Presentations
PubMed
- Federal and Industry Sponsorship in US Cancer Clinical Trials.Joseph M Unger, Hong Xiao, Michael L LeBlanc, Dawn L Hershman
JAMA Oncology. 2026-08-20 - Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.Claudine Isaacs, Rita Nanda, Christina Yau, A Jo Chien, Dawn L Hershman
JAMA Oncology. 2026-07-30 - Adolescents and Young Adults With Acute Lymphoblastic Leukemia: Qualitative Barriers and Facilitators to Guideline-Concordant Care.Allison C Grimes, Julie A Wolfson, Charlotte L Kerber, Kristin M Bingen, Melissa P Beauchemin
Cancer Control. 2026-07-20
Journal Articles
- Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women with Early-Stage Breast CancerA Randomized Clin...Dawn L Hershman, Jillian L Capodice, William H Kreisle, Michael J Fisch, Marianne K Melnik, Alice T Kengla, Carla W Jorgensen, Heather Greenlee, JAMA
- Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology StatementLigibel JA, Alfano CM, Hershman DL, Ballard RM, Bruinooge SS, Courneya KS, Daniels EC, Demark-Wahnefried W, Frank ES, Goodwin PJ, Irwin ML, Levit LA, McCaskill-Stevens..., J Clin Oncol, 1/31/2015
- Population-based assessment of determining predictors for quality of prostate cancer surveillanceChamie K, Williams SB, Hershman DL, Wright JD, Nguyen PL, Hu JC, Cancer, 1/26/2015
Books/Book Chapters
Lectures
- Association of baseline cardiovascular risk factors and health care utilization and costs in elderly breast cancer patients enrolled in SWOG clinical trials.2019 ASCO Annual Meeting - 6/1/2019
- Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105.2019 ASCO Annual Meeting - 6/1/2019
- Long Term Consequences of Intermittent and Continuous Androgen Deprivation in Patients with Metastatic Prostate Cancer1/1/2015
Authored Content
- Characteristics Associated with Prolonged Length of Stay After Hysterectomy for Benign Gynecologic ConditionsMay 2018
Press Mentions
Federal and Industry Sponsorship in US Cancer Clinical TrialsAugust 20th, 2026
This 25-Year-Old Survived Breast Cancer. Now, She's Dealing with MenopauseJuly 31st, 2025
Genetic Counseling Tool Cuts Physician Explanation Time by 64%, Improves Patient UnderstandingJune 6th, 2025
Grant Support
- SWOG Network Group Operations Center of the NCTNUNIVERSITY OF CALIFORNIA AT DAVIS2014–2032
- Elasticity imaging of breast cancer during treatmentCOLUMBIA UNIVERSITY HEALTH SCIENCES2026–2031
- Elasticity imaging of breast cancer during treatmentCOLUMBIA UNIVERSITY HEALTH SCIENCES2026–2031
- Molecular Oncology Training ProgramCOLUMBIA UNIVERSITY HEALTH SCIENCES2016–2031
- CUIMC Calabresi Clinical Oncology Career Development ProgramCOLUMBIA UNIVERSITY HEALTH SCIENCES2024–2029
Professional Memberships
- Member
Insurance Accepted
- Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPOGHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









